Uramustine

Uramustine

Uramustine is a chemotherapy drug that belongs to the class of alkylating agents. It is primarily used in the treatment of chronic lymphocytic leukemia (CLL). Uramustine is a derivative of uracil, a component of RNA, and is chemically related to the nitrogen mustard class of drugs.

Mechanism of Action

Uramustine works by interfering with the DNA replication process in cancer cells. As an alkylating agent, it forms covalent bonds with the DNA, leading to cross-linking of DNA strands. This cross-linking prevents the cancer cells from dividing and ultimately results in cell death. The uracil component of uramustine allows it to be incorporated into the nucleic acids of rapidly dividing cells, enhancing its cytotoxic effects.

Clinical Use

Uramustine is specifically indicated for the treatment of chronic lymphocytic leukemia. It is administered intravenously and dosage is determined based on the patient's body surface area and overall health condition. The drug is often used in combination with other chemotherapy agents to enhance its efficacy.

Side Effects

Like many chemotherapy drugs, uramustine can cause a range of side effects. Common side effects include nausea, vomiting, myelosuppression (decreased production of blood cells), and increased risk of infection. Patients may also experience hair loss, fatigue, and mucositis. Long-term use of uramustine can lead to secondary malignancies due to its mutagenic potential.

Related Pages

• Chronic lymphocytic leukemia
• Alkylating agent
• Chemotherapy
• Nitrogen mustard

References

Chemical structure of Uramustine